ghadmin
Cancer Screening by the PCP: Advanced Practice Provider or Physician?
Screening saves lives. The first conversation most people will have around screening is with a Primary Care Provider (PCP). Now, when you read or hear the words PCP do you think of a physician or another form of provider?
Blood tests may spare cancer patients chemo
A blood test which can detect traces of cancer cells could spare thousands of patients unnecessary chemotherapy every year.
Guardant Health applauds proposed FY2024 budget increases and pledges support for the Biden-Harris Administration Moonshot goal to end cancer as we know it
Reducing the death rate from cancer by at least 50 percent over the next 25 years and improving the experience of people and families living with and surviving cancer is a hallmark of Guardant Health’s patient-first philosophy.
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
The final module of its premarket approval (PMA) application for Shield™, Guardant Health’s blood test to screen for colorectal cancer (CRC).
Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation as Detected by Guardant Health’s Guardant360 CDx Liquid Biopsy
Prospective screening of subjects for ESR1 mutations will use the Guardant360 CDx blood test for companion diagnostic development
The Woman’s Impact on Colorectal Cancer Screening
March is a month to celebrate. A month to celebrate women and a month to celebrate the progress we have made in Colorectal Cancer (CRC) Screening. President Bill Clinton declared March as National Colorectal Cancer Awareness Month in 2000, while Congress declared March as Women’s History month in 1987.8,9 Today, we celebrate by looking at the evolving role of the Women’s Health Nurse Practitioner (WHNP) and its impact on CRC Screening, both of which are very near and dear to my heart. As a clinician, I provide healthcare to women where screening for colorectal cancer is a key preventive measure.
Musa Tariq Joins Guardant Health Board of Directors
Currently the chief marketing officer for GoFundMe, the world’s leading fundraising platform, Tariq is a distinguished marketing executive with experience leading global consumer brands.
Liquid Biopsy: Unlocking New Insights to Help Improve Outcomes for Cancer Patients
What if a simple blood draw taken during a routine visit to the doctor for a check-up or a flu shot could allow us to identify specific cancers at an early stage, when they are the most treatable? What if blood tests could help the cancer care team improve patient care at every step of the patient’s journey—from detection to treatment selection to response and recurrence monitoring?
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Shield ™ blood test will be used to evaluate whether blood test option improves adherence to colorectal cancer screening recommendations in medically underserved populations at Federally Qualified Health Centers
Achieving Diversity in Clinical Trials: Charting a More Equitable Path for Research
One year ago, President Biden reinstated the Cancer Moonshot to reduce the nation’s cancer burden and shed light on inequities in cancer care, calling on both the public and private sectors to help meet this challenge. One area where industry can take initiative is ensuring research and clinical trials capture a diverse patient population.